Literature DB >> 15374998

Functional interaction between tumor suppressor menin and activator of S-phase kinase.

Robert W Schnepp1, Zhaoyuan Hou, Haoren Wang, Clark Petersen, Albert Silva, Hisao Masai, Xianxin Hua.   

Abstract

Multiple endocrine neoplasia type I (MEN1), a hereditary tumor syndrome, is characterized by the development of tumors in multiple endocrine organs. The gene mutated in MEN1 patients, Men1, encodes a tumor suppressor, menin. Overexpression of menin leads to inhibition of Ras-transformed cells. However, it is unclear whether menin is essential for repression of cell proliferation, and if it is, how it inhibits cell proliferation. Here, we show that targeted disruption of the Men1 gene leads to enhanced cell proliferation, whereas complementation of menin-null cells with menin reduces cell proliferation. Moreover, menin interacts with activator of S-phase kinase (ASK), a component of the Cdc7/ASK kinase complex that is crucial for cell proliferation, but does not appear to alter Cdc7 kinase activity in in vitro kinase assays. We identify the COOH terminus of menin as the domain that mediates the specific interaction with ASK. Notably, wild-type menin completely represses ASK-induced cell proliferation, although it does not obviously affect the steady-state cell cycle profile of ASK-infected cells. Interestingly, disease-related COOH-terminal menin mutants that do not interact with ASK completely fail to repress ASK-induced cell proliferation. Together, these findings demonstrate a functional link between menin and ASK in the regulation of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374998     DOI: 10.1158/0008-5472.CAN-04-0724

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Trithorax group proteins: switching genes on and keeping them active.

Authors:  Bernd Schuettengruber; Anne-Marie Martinez; Nicola Iovino; Giacomo Cavalli
Journal:  Nat Rev Mol Cell Biol       Date:  2011-11-23       Impact factor: 94.444

2.  TNIP1, a retinoic acid receptor corepressor and A20-binding inhibitor of NF-κB, distributes to both nuclear and cytoplasmic locations.

Authors:  Igor Gurevich; Carmen Zhang; Nidhish Francis; Brian J Aneskievich
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 3.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

4.  MEN1 family with a novel frameshift mutation.

Authors:  V Nuzzo; L Tauchmanová; A Falchetti; A Faggiano; F Marini; S Piantadosi; M L Brandi; L Leopaldi; A Colao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

5.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

Review 6.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 7.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

Review 8.  Clinical and molecular genetics of parathyroid neoplasms.

Authors:  John M Sharretts; William F Simonds
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

9.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

Review 10.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.